02:23:13 Europe / Stockholm

Prenumeration

2024-05-22 15:06:00

Redeye resumes its coverage and updates its view on BeammWave after BeammWave concluded its right issue. After the rights issue and conditional on a successful warrant exercise rate, Redeye believes BeammWave has sufficient funding. The Highlight of Q1 2024 was that BeammWave booked its first net sales as the Molex project was delivered. Redeye adjusts its estimates and fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/